drugset
drugset / Trial / NCT04898101

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

NCT04898101 ↗

Phase 1 Completed 14 enrolled Acerta Pharma BV
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is to determine the absolute bioavailability of oral acalabrutinib and intravenous (IV) PK of \[14C\]ACP-196.

Timeline

Start
2016-03-03
Primary completion
2016-04-13
Completion
2016-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule 100 mg Oral

Indications

No indication recorded.